Fig. 1 · Structure

Documents & Downloads

Ganciclovir

Cat. No. A11645 CAS 82410-32-0
Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
CMV  
HSV-1  
HSV-2  
FHV-1 IC50 5.2 μM

Cellular Effect

Cell Line Activity Value Description Reference
BC-3 IC50 70 μM Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay [PMID: 17402726]
BJ EC50 3 μM Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days [PMID: 18458124]
Bone marrow cell CC50 30 μM Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days [PMID: 17329103]
BSC-1 IC50 3.5 μM Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay [PMID: 15509176]
BSC-1 IC50 3.5 μM Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay [PMID: 15509175]
BSC-1 IC50 3.5 μM Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay [PMID: 15509174]
BSC-1 IC50 3.5 μM ELISA assay was performed using BSC-1 cells to determine activity against HSV-1 [PMID: 10882372]
BSC-1 IC50 3.5 μM Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells [PMID: 10882370]
CCRF-CEM CC50 > 100 μM Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method [PMID: 28829913]
CCRF-CEM IC50 > 390 μM In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity [PMID: 11814776]
DG-75 IC50 > 100 μM Cytotoxicity against DG75 cells after 120 hrs by MTT assay [PMID: 17402726]
E6SM EC50 > 100 μg/mL Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 > 100 μM Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines [PMID: 11495586]
E6SM EC50 0.0012 μM Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines [PMID: 11495586]
E6SM EC50 0.0012 μM Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines [PMID: 11495586]
E6SM EC50 0.003 μg/mL Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 0.004 μg/mL Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 2.4 μg/mL Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
Fibroblast EC50 1.2 μM Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay [PMID: 19397271]

19 records · Scroll to view more

Ganciclovir Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Ganciclovir from 3 published references. In vivo models include aged p16‐3MR mice.

Ganciclovir In Vitro Studies

Ganciclovir was tested at varying concentrations in serum-starved mouse microglial cells. It inhibited microglial proliferation assessed by thymidine incorporation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Microglial proliferation in cultured mouse cells

Cell-based study · BV-2 mouse microglial cells; n = 3 wells/group [1]

Mouse microglial cells received varying concentrations of Ganciclovir following serum starvation. Ganciclovir inhibited proliferation assessed by thymidine incorporation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell proliferation by thymidine incorporationReported result BV-2 cells: serum starved for an additional 12 h before the addition of varying concentrations of GCV for a total of 24 h; GCV inhibits microglial proliferation in vitro.[1]

Literature-Reported Treatment Conditions

Exposure duration
a total of 24 h
Method
addition of varying concentrations of GCV
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Ganciclovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIAL AND METHODS > Untitled > Proliferation assay. (S37, S38); Figure 6. legend (S132, S143, S144)

cell proliferation by thymidine incorporation: cell proliferation by thymidine incorporation — MATERIAL AND METHODS > Untitled > Proliferation assay. (S37); Figure 6. legend (S132)

Ganciclovir In Vivo Studies

Daily intraperitoneal Ganciclovir strongly inhibited EAE and neuroinflammation in mice compared with PBS vehicle. In aged naïve mice, Ganciclovir treatment produced a trending reduction in the population expressing SA‐β‐gal within lung CD45+ cells. In another study of aged mice, Ganciclovir decreased blood–brain barrier permeability for all fluorescent tracers tested compared with vehicle, bringing permeability closer to young control levels. [1,2,3]

GCV strongly inhibits EAE and neuroinflammation beginning at 7 d.p.i.

Animal study · mice; EAE; n = 10–15 mice/group [1]

Mice were treated daily with PBS (vehicle) or 100 mg/kg GCV beginning at 7 d.p.i. GCV strongly inhibits EAE and neuroinflammation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Disease severityReported result 100 mg/kg GCV beginning at 7 d.p.i.: mice were treated daily; GCV strongly inhibits EAE and neuroinflammation.[1]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
daily; beginning at 7 d.p.i.
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ganciclovir 100 mg/kgPBS (vehicle)100 mg/kg GCV beginning at 7 d.p.i.: mice were treated daily; GCV strongly inhibits EAE and neuroinflammation.[1]
Ganciclovir 100 mg/kg
Model: mice; EAE; n = 10–15 mice/group
Methods and source locations

Compound reported in the paper: Ganciclovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIAL AND METHODS > Untitled > GCV, IFN-β, and mitoxantrone treatments. (S11); Figure 1. legend (S70); Figure 2. legend (S100, S101, S103, S104)

Disease severity: Disease severity; comparator: PBS (vehicle) — Figure 2. legend (S100, S101, S103)

Ganciclovir 100 mg/kg · MATERIAL AND METHODS > Untitled > GCV, IFN-β, and mitoxantrone treatments. (S11); Figure 2. legend (S100, S101)

Lung senescence marker expression in aged mice

Animal study · aged (18–20mo) male and female p16‐3MR mice on a C57BL/6 genetic background; Between 4 and 8 aged mice per treatment group [2]

Aged male and female mice received intraperitoneal Ganciclovir or equal-volume PBS injections. In naïve mouse lungs, the Ganciclovir-treated group showed a trending reduction in the population expressing SA‐β‐gal within CD45+ cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
In the CD45+ population; population expressing SA‐β‐gal (Q1)Reported result 25 mg/kg/day; in the lungs of naïve mice: In the CD45+ population, we observed a trending reduction in the population expressing SA‐β‐gal (Q1) in the GCV‐treated group.[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
five consecutive days
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ganciclovir 25 mg/kg/dayControl mice were injected with equal volume PBS.25 mg/kg/day; in the lungs of naïve mice: In the CD45+ population, we observed a trending reduction in the population expressing SA‐β‐gal (Q1) in the GCV‐treated group.[2]
Ganciclovir 25 mg/kg/day
Model: aged (18–20mo) male and female p16‐3MR mice on a C57BL/6 genetic background; Between 4 and 8 aged mice per treatment group
Methods and source locations

Compound reported in the paper: Ganciclovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS > Mice (S1, S2); METHODS > Ganciclovir (GCV) treatment (S8, S9, S10); RESULTS > Untitled (S58, S60)

In the CD45+ population; population expressing SA‐β‐gal (Q1): In the CD45+ population; population expressing SA‐β‐gal (Q1); comparator: Control mice were injected with equal volume PBS. — METHODS > Ganciclovir (GCV) treatment (S8); RESULTS > Untitled (S58, S60)

Ganciclovir 25 mg/kg/day · METHODS > Ganciclovir (GCV) treatment (S8, S10); RESULTS > Untitled (S58, S60)

Ganciclovir Decreases Blood–Brain Barrier Permeability in Aged Mice

Animal study · aged p16‐3MR mice [3]

Aged mice received intraperitoneal Ganciclovir, with vehicle as the control. Senolytic treatment with Ganciclovir effectively decreased blood–brain barrier permeability for all fluorescent tracers tested, bringing permeability closer to levels observed in young control mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Two‐photon‐imaging‐based measurement of microvascular permeability to fluorescent tracersReported result In aged mice, senolytic treatment with GCV effectively decreased BBB permeability for all tracers tested one‐month post‐treatment (B: 40 kDa; C: 3 kDa; D: 0.3 kDa), aligning it more closely with the permeability levels observed in young control mice.[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
daily; 5 days, across two treatment cycles, with a 2‐week resting period between cycles
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ganciclovir 25 mg/kgvehicleIn aged mice, senolytic treatment with GCV effectively decreased BBB permeability for all tracers tested one‐month post‐treatment (B: 40 kDa; C: 3 kDa; D: 0.3 kDa), aligning it more closely with the permeability levels observed in young control mice.[3]
Ganciclovir 25 mg/kg
Model: aged p16‐3MR mice
Methods and source locations

Compound reported in the paper: Ganciclovir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Senolytic Treatments (S13, S14); Materials and Methods > Cranial Window Surgery Protocol (S141); Materials and Methods > Measurement of Blood–Brain Barrier Integrity and Microvascular Density Using Intravital Two‐Photon Microscopy (S145, S148); FIGURE 5 legend (S372, S377)

Two‐photon‐imaging‐based measurement of microvascular permeability to fluorescent tracers: Two‐photon‐imaging‐based measurement of microvascular permeability to fluorescent tracers; comparator: vehicle — FIGURE 5 legend (S372, S377)

Ganciclovir 25 mg/kg · Materials and Methods > Senolytic Treatments (S13, S14); FIGURE 5 legend (S377)

Specifications

Manufacturer Adooq Bioscience
CAS Number 82410-32-0
Formula C9H13N5O4
Molecular Weight 255.23
Synonyms Cytovene
SMILES
C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 25 mg/mL (97.94 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
4% DMSO+30% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ganciclovir Research References

  1. [1] Ding Z, Mathur V, Ho PP, et al. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J Exp Med (2014). PMID: 24493798 DOI: 10.1084/jem.20120696 Source material
  2. [2] Torrance BL, Cadar AN, Panier HA, et al. Cellular senescence is a double-edged sword in regulating aged immune responses to influenza. Aging Cell (2024). PMID: 38689516 DOI: 10.1111/acel.14162 Source material
  3. [3] Csik B, Nyúl-Tóth Á, Gulej R, et al. Senescent Endothelial Cells in Cerebral Microcirculation Are Key Drivers of Age-Related Blood-Brain Barrier Disruption, Microvascular Rarefaction, and Neurovascular Coupling Impairment in Mice. Aging Cell (2025). PMID: 40167015 DOI: 10.1111/acel.70048 Source material

Added to your cart

View Cart Checkout
Loading...